JP2023513750A - 耐性呼吸細菌における感受性の改善及び抗生物質耐性の低下のための外因性一酸化窒素 - Google Patents

耐性呼吸細菌における感受性の改善及び抗生物質耐性の低下のための外因性一酸化窒素 Download PDF

Info

Publication number
JP2023513750A
JP2023513750A JP2022548911A JP2022548911A JP2023513750A JP 2023513750 A JP2023513750 A JP 2023513750A JP 2022548911 A JP2022548911 A JP 2022548911A JP 2022548911 A JP2022548911 A JP 2022548911A JP 2023513750 A JP2023513750 A JP 2023513750A
Authority
JP
Japan
Prior art keywords
cos
antibiotic
nitric oxide
microorganism
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022548911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513750A5 (https=
Inventor
マーク エイチ． ショーンフィッシュ，
ケイトリン ローズ ルイヤール，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2023513750A publication Critical patent/JP2023513750A/ja
Publication of JP2023513750A5 publication Critical patent/JP2023513750A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicinal Preparation (AREA)
JP2022548911A 2020-02-14 2021-02-11 耐性呼吸細菌における感受性の改善及び抗生物質耐性の低下のための外因性一酸化窒素 Ceased JP2023513750A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062976738P 2020-02-14 2020-02-14
US62/976,738 2020-02-14
US202063125865P 2020-12-15 2020-12-15
US63/125,865 2020-12-15
PCT/US2021/017711 WO2021163367A1 (en) 2020-02-14 2021-02-11 Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria

Publications (2)

Publication Number Publication Date
JP2023513750A true JP2023513750A (ja) 2023-04-03
JP2023513750A5 JP2023513750A5 (https=) 2024-02-20

Family

ID=77292649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548911A Ceased JP2023513750A (ja) 2020-02-14 2021-02-11 耐性呼吸細菌における感受性の改善及び抗生物質耐性の低下のための外因性一酸化窒素

Country Status (6)

Country Link
US (1) US20230082968A1 (https=)
EP (1) EP4103199A4 (https=)
JP (1) JP2023513750A (https=)
CN (1) CN115209905A (https=)
AU (1) AU2021218708B2 (https=)
WO (1) WO2021163367A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114191559A (zh) * 2021-11-04 2022-03-18 陕西省微生物研究所 一种no增强抗生素抗菌敏感性的方法及应用
CN119789870A (zh) * 2022-06-08 2025-04-08 诺欧生物有限责任公司 含有一氧化氮释放化合物的多组分药物组合物和试剂盒及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297200A1 (en) * 2007-10-12 2010-11-25 The University Of North Carolina Atchapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
JP2015524877A (ja) * 2012-08-17 2015-08-27 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 水溶性一酸化窒素放出ポリグルコサミンおよびそれらの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125262A1 (en) * 2005-05-24 2006-11-30 Environmental Biotechnology Crc Pty Limited Methods and compositions for regulating biofilm development

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297200A1 (en) * 2007-10-12 2010-11-25 The University Of North Carolina Atchapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
JP2015524877A (ja) * 2012-08-17 2015-08-27 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 水溶性一酸化窒素放出ポリグルコサミンおよびそれらの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATELYN P.REIGHARD ET AL., BIOFOULING, vol. Vol.31, Nos.9-10, JPN6025004881, 2015, pages 775 - 787, ISSN: 0005521975 *
ROUILLARD, K.R. ET AL., PEDIATRIC PULMONOLOGY, vol. Vol.53, Issue S2, JPN6025004880, 2018, pages 283 - 284, ISSN: 0005521974 *

Also Published As

Publication number Publication date
US20230082968A1 (en) 2023-03-16
AU2021218708A1 (en) 2022-09-29
EP4103199A1 (en) 2022-12-21
AU2021218708B2 (en) 2024-10-03
EP4103199A4 (en) 2024-04-03
CN115209905A (zh) 2022-10-18
WO2021163367A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
Rouillard et al. Exogenous nitric oxide improves antibiotic susceptibility in resistant bacteria
Mohamed et al. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate
Liu et al. Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine
Konai et al. Structure–activity relationship of amino acid tunable lipidated norspermidine conjugates: disrupting biofilms with potent activity against bacterial persisters
AU2021218708B2 (en) Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria
Grayton et al. Biofilm dispersal, reduced viscoelasticity, and antibiotic sensitization via nitric oxide-releasing biopolymers
DK2714034T3 (en) COMPOSITIONS INCLUDING CEFEPIM AND TAZOBACTAM
Ramirez et al. Guanidinylated amphiphilic tobramycin derivatives synergize with β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa
CA3171167A1 (en) Exogenous nitric oxide for improved susceptibility and lowered antibiotic resistance in resistant respiratory bacteria
EP3116545A1 (en) Pharmaceutical compositions comprising antibacterial agents
JP2016538262A (ja) 抗菌剤を含む医薬品組成物
WO2015125031A1 (en) Pharmaceutical combinations comprising antibacterial agents
ES2902456T3 (es) Composiciones farmacéuticas que comprenden agentes antibacterianos
Cao et al. Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide
JP2016535038A (ja) 抗菌剤を含む医薬品組成物
US20210290648A1 (en) Potentiation of B-Lactam Antibiotics and B-Lactam/B-Lactamase Inhibitor Combinations Against Multidrug and Extensively Drug-Resistant Pseudomonas Aeruginosa Using Non-Ribosomal Tobramycin-Cyclam Conjugates
Ayad Al-Tawee et al. The combined impact of chlorhexidine digluconate and chitosan as microbicide agents against the prevailing MDR Pseudomonas aeruginosa isolates from Iraqi patients: An in vitro study.
UA115539C2 (uk) Фармацевтична композиція та набір для лікування бактеріальних інфекцій
Laughlin-Black et al. Interspecies synergism and antagonism induce differential and potentially exploitable susceptibility to various classes of antibiotics in a wound-like polymicrobial community
Rouillard Characterization of Pseudomonas aeruginosa Susceptibility to Nitric Oxide and Antibiotics Under Cystic Fibrosis-Relevant Conditions
Chosy Combatting Bacterial Pathogens: Design, Evaluation, and Introduction of Novel Guanidinium-Rich Antibiotic Conjugates
EP3125887A1 (en) Pharmaceutical compositions comprising cefepime or sulbactam
RU2705375C2 (ru) Фармацевтические композиции, содержащие антибактериальные агенты
Shrivastava et al. Comparative antimicrobial activity of ceftazidime, tobramycin and their novel fixed dose combination in some pathogenic microorganisms
CN114073771A (zh) 用于杀菌的组合物、其应用以及药物制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251107

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260327